NCT06494436 Microvention AnEurysm & STroke Real-life Data cOllection
| NCT ID | NCT06494436 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Microvention-Terumo, Inc. |
| Condition | Intracranial Aneurysm |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-12-30 |
| Primary Completion | 2029-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-12-30 with a primary completion date of 2029-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry
Eligibility Criteria
Inclusion criteria: * Patient, or another authorized person as per country-specific regulations, is informed of the data collection and gives non-opposition or consent prior to the data collection in accordance with institutional and geographic requirements. * For Cohort 1, patient is treated for a ruptured or unruptured intracranial aneurysm using a commercially available MicroVention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study. * For Cohort 2, patient is treated using a commercially available MicroVention mechanical thrombectomy device as the first-line treatment strategy and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study. Note: For the purposes of this protocol, ancillary/accessory devices such as balloon catheters, carotid stent for extracranial stenosis and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices. Exclusion Criteria: * Patient is or is expected to be inaccessible for follow-up. * Patient is participating or intends to participate in another study that changes the site practice. * Patient is already participating in the MAESTRO study for the same pathology.
Contact & Investigator
Alejandro Tomasello, MD
STUDY CHAIR
University Hospital Vall D'Hebron
Frequently Asked Questions
Who can join the NCT06494436 clinical trial?
This trial is open to participants of all sexes, studying Intracranial Aneurysm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06494436 currently recruiting?
Yes, NCT06494436 is actively recruiting participants. Contact the research team at mveclinicalemea@microvention.com for enrollment information.
Where is the NCT06494436 trial being conducted?
This trial is being conducted at Vigo, Spain.
Who is sponsoring the NCT06494436 clinical trial?
NCT06494436 is sponsored by Microvention-Terumo, Inc.. The principal investigator is Alejandro Tomasello, MD at University Hospital Vall D'Hebron. The trial plans to enroll 1,000 participants.